# Aeterna Zentaris

Source: https://onco.cc/companies/aeterna-zentaris/  
OnCo record `aeterna-zentaris` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Aeterna Zentaris is a Frankfurt-based biotech whose oncology programmes, including the alkylphospholipid perifosine and the LHRH antagonist ozarelix, went through phase 3 trials it led; its approved product is a growth hormone deficiency test.

## Summary

Aeterna Zentaris, headquartered in Frankfurt am Main and listed in Toronto and on Nasdaq, developed cancer drug candidates including perifosine (tested in phase 3 in multiple myeloma and colorectal cancer) and zoptarelin doxorubicin (a doxorubicin-LHRH conjugate tested in endometrial cancer), none of which reached approval. Its marketed product, macimorelin, is a diagnostic for adult growth hormone deficiency. It appears on ClinicalTrials.gov as lead sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: AEterna Zentaris; Aeterna Zentaris Inc.; Zentaris GmbH
- Tags: ctgov-sponsor
- HQ: Frankfurt
- Type: biotech
- Website: https://www.aezsinc.com

## Sources

- Official website: https://www.aezsinc.com
- ClinicalTrials.gov: trials led by AEterna Zentaris: https://clinicaltrials.gov/search?lead=AEterna%20Zentaris
- Wikidata: https://www.wikidata.org/wiki/Q30268820

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/aeterna-zentaris.json